AEOL 10150 increases regeneration of GI stem cells: NIAID study results Aeolus Pharmaceuticals.

These scholarly studies are being carried out by Epistem, a subcontractor of the University of Maryland, in compliance with requirements of the FDA that are a pre-requisite for movement of the Aeolus drug along the pathway for FDA licensure to treat lethally irradiated people in case of a terrorist nuclear take action. Related StoriesSausages With Antioxidants From Berries TO AVOID CancerCornell biomedical engineers develop 'super natural killer cells' to destroy tumor cells in lymph nodesFDA grants accelerated approval for Tagrisso to take care of patients with advanced NSCLCThe NIH NIAID Radiation/Nuclear Medical Countermeasure Development program leads the U.S. Effort to develop remedies for radiation sickness following a nuclear terrorist assault.‘One barrier to the present ways of testing such toxins has been that rats and mice are only subjected to one chemical at a time, which decreases the assessment of dangers and will not address the fact that folks are exposed to several chemicals simultaneously in real life, a lot of which interact with each other.’ A primary goal of the multidisciplinary research will be to include finding ways to increase the testing procedure and decrease the costs. This can be done through the use of zebrafish in the studies to be performed at UH, which is a new approach that will complement Texas A&M’s use of mouse embryonic stem cells in this task.

Copyright 2018